

CorNotes

CVI SEMINAR SERIES

The next CVI-Research Division Seminar will be held on **Thursday, May 15, 2008 at 4:00 pm** in **The Van Kampen Conference Center, Building 110, Room 6274**. Our speaker will be:

Pamela A. Lucchesi, Ph.D.
**Director, Center for Cardiovascular
and Pulmonary Research**
Nationwide Children's Hospital
Columbus, Ohio

The title of Dr. Lucchesi's seminar is:

"Coronary Artery Remodeling in Type II Diabetes"

For further information about the CVI Seminar Series, contact Dr. Leanne Cribbs at x72817.

CVI JOURNAL CLUB

May 8.....D. Chaturvedi
May 22.....L. Brueggemann

CVI Journal Club is held at 12:00 noon in the CVI Research Division Conference Room, Rm 5215. For further information, contact Dr. Ken Byron at x72819.

CARDIOLOGY – CVI RESEARCH DIVISION BASIC SCIENCE SEMINAR

The Cardiology Division and the CVI Research Division are sponsoring a series of joint seminars by Loyola Faculty. The following seminar is scheduled at **7:30 am** in the **Van Kampen Conference Center**:

May 8.....Dr. R. Mestril

The title of Dr. Mestril's talk is:

**"At the Intersection of Diabetes and
Cardiovascular Disease"**

For more information about this seminar series, contact Dr. Samarel at x72821.

BALANCE CLINICAL TRIAL

Dr. Alain Heroux of the section of Heart Failure and HeartTransplant is the principal investigator conducting the BALANCE clinical trial on behalf of Caridiokine to determine whether administration of lixivaptan can effectively and safely produce an increase in serum sodium from baseline in heart failure patients with volume overload and hyponatremia.

Phase I and Phase II clinical trials have demonstrated that lixivaptan may play an important role in treating hyponatremia and the signs and symptoms of water retention associated with HF, liver cirrhosis with ascites (LCWA) and syndrome of inappropriate antidiuretic hormone (SIADH). Lixivaptan was previously evaluated in disease states characterized by hyponatremia with euvolemia (SIADH) and hyponatremia combined with fluid overload (HF, LCWA). Lixivaptan effected a correction in hyponatremia together with a marked diuresis in subjects with volume overload. The present study is designed to confirm and extend the observations from previous studies that lixivaptan therapy corrects hyponatremia, improves fluid balance, and provides clinical benefit for subjects with HF and volume overload.

For more information or to alert the Heart Failure/Transplant team of potential participants, please contact the project's coordinator, Cindy Finn, at 708-216-2646.

RECENT PUBLICATIONS FROM THE CVI

Akar J, Jeske W, Wilber DJ. Acute onset atrial fibrillation is associated with local cardiac platelet activation and endothelial dysfunction. *J Am Coll Cardiol* 51:1790-1793, 2008.

Khare S, Mustafi R, Cerda S, Yuan W, Jagadeeswaran S, Dougherty U, Tretiakova M, Samarel AM, Cohen G, Wang J, Moore C, Wali R, Holgren C, Joseph L, Fichera A, Li YC, Bissonette M. Ursodeoxycholic acid suppresses Cox-2 expression in colon cancer: roles of Ras, p38 and CCAAT/Enhancer-Binding Protein. *Nutrition and Cancer*, 60:389-400, 2008.